Recurrence of Retinopathy of Prematurity in Zone II Stage 3+ after Ranibizumab Treatment: A Retrospective Study

Table 1

Univariate analysis of baseline demographics and recurrence in the eyes with retinopathy of prematurity in Zone II Stage 3 after ranibizumab treatment.

	Recurrence (18 eyes)	Favorable outcome (62 eyes)	value
Baseline characteristics
Patients	11	31
Birth weight (g)	1204.09 ± 321.36	1356.61 ± 505.10	0.311^a
Gestation age (weeks)	28.82 ± 1.36	29.72 ± 2.39	0.112^a
Male	5	17	1.000^b
Multiple gestation	2	11	0.713^b
Respiratory distress syndrome	4	11	0.481^b
Sepsis	0	1	1.000^b
HIE	1	0	0.262^b
Anemia	4	12	0.720^b
Pneumonia	1	6	1.000^b
Hypotension	1	1	0.387^b
Carbohemia	1	1	0.387^b
Intraventricular hemorrhage	2	8	1.000^b
Blood transfusion	2	8	1.000^b
Oxygen administration	6	20	1.000^b
Surfactant	0	7	0.654^b
Vitamin E	1	2	1.000^b
Hormones	1	0	0.262^b
Factors during pregnancy
Preeclampsia	2	2	0.558^b
Placental abruption	0	4	0.330^b
Intrauterine hypoxia	1	3	0.558^b
ROP findings
Preretinal hemorrhage before treatment	5	6	0.000^b
Preretinal hemorrhage after treatment	0	2	0.216^b
Iris neovascularization	1	0	0.349^b
Threshold	17	52	0.254^b

^aIndependent samples t-test.
^bChi-square test.
SD: standard deviation; HIE: hypoxic ischemic encephalopathy; ROP: retinopathy of prematurity.